. 2022 Feb 24;9:820178. doi: 10.3389/fcvm.2022.820178

Table 2.

The Cox regression analysis with risk factors for all-cause mortality in patients with HFpEF.

Worsening LVEF vs. Non- worsening LVEF	HR (95% CI)	P-value
Model^a	1.79 (1.19–2.70)	0.006
Model^b	2.12 (1.32–3.39)	0.002
Model^c	2.18 (1.35–3.52)	0.001

Model^a: Adjustment for demographics (age and sex).

Model^b: Adjustment for demographics (age and sex), left ventricular ejection fraction, N-terminal pro-B-type natriuretic peptide, high-density lipoprotein cholesterol, estimated glomerular filtration rate, coronary artery disease, acute myocardial infarction, percutaneous coronary intervention, atrial fibrillation, diabetes mellitus, and hypertension.

Model^c: Adjustment for demographics (age and sex), left ventricular ejection fraction, N-terminal pro-B-type natriuretic peptide, high-density lipoprotein cholesterol, estimated glomerular filtration rate, coronary artery disease, acute myocardial infarction, percutaneous coronary intervention, atrial fibrillation, diabetes mellitus, hypertension, spirolactone, angiotension-converting enzyme inhibitor or angiotension receptor blocker, and diuretic.